Doxifin 200-mg Tablets Veterinary Use Broad spectrum antimicrobial based on doxycycline Formula: Each soluble 600-mg tablet contains: Doxycycline hyclate.223.00 mg (*) Excipient q.s.p.600.00 mg * Equal to 200.00 mg of doxycycline basis. General information Doxycycline is an antibiotic from tetracycline family, with some particularities that differentiate it from other congenerous molecules. It has high oral absorption (about 95%), with prolonged half-life (approximately 18 to 24 hours), therefore needing daily dosages lower than other tetracyclines. The presence of food in the stomach does not interfere in the doxycycline absorption. It has excellent distribution and penetration in most liquids and organic tissues. It presents the highest liposolubility degree among all tetracyclines, which facilitates the direct penetration of the active drug through the double lipid layer of infectious agents, even reaching some strains resistant to other tetracyclines. It acts inhibiting the protein synthesis of sensitive etiological agents. Doxycycline does not accumulates significantly in the circulation of animals with kidney failure. Thus, it constitutes the safest tetracycline in the treatment of extra-renal infections in these animals. Doxycycline is excreted in feces, in most part as an inactive conjugate, or maybe, as chelate; because of this, its impact on the intestinal microflora is relatively smaller. The tablets are soluble in liquids, aiming to facilitate the administration by oral route, which can be as tablet or suspension. Indications Doxifin 200-mg Tablets is indicated for treatment of several illnesses that affect dogs and cats, caused by the following etiological agents sensitive to doxycycline: For dogs: Respiratory infections: (Staphylococcus spp, Streptococcus spp, Haemophilus spp, Mycoplasma spp) Urinary infections: (Staphylococcus spp, Streptococcus spp, Escherichia coli) Anaplasmosis: (Anaplasma spp) Canine erhlichiosis: (Ehrlichia canis) Leptospirosis: (Leptospira spp) Pododermatitis: (Fusobacterium spp, Staphylococcus spp) Diarrheas and gastroenteritides: (Escherichia coli, Salmonella spp) Tetanus: (Clostridium tetani) Otitis: (Staphylococcus spp, Streptococcus spp, Pasteurella multocida) Infected wounds and post-operatory: (Staphylococcus spp, Streptococcus spp, Corynebacterium spp, Escherichia coli, Pasteurella multocida) For cats: Respiratory infections (Staphylococcus spp, Streptococcus spp, Haemophilus spp, Mycoplasma spp)
Urinary infections: (Staphylococcus spp, Streptococcus spp, Escherichia coli) Leptospirosis: (Leptospira spp) Pododermatitis: (Fusobacterium spp, Staphylococcus spp) Diarrheas and gastroenteritides: (Escherichia coli, Salmonella spp) Tetanus: (Clostridium tetani) Otitis: (Staphylococcus spp, Streptococcus spp, Pasteurella multocida) Infected wounds and post-operatory: (Staphylococcus spp, Streptococcus spp, Corynebacterium spp, Escherichia coli, Pasteurella multocida) Mode of use and dosage Doxifin 200-mg Tablets must be administered by oral route, in the dosage: Doxifin Tablets Bodyweight
one 200-mg tablet
that is, 5 mg of doxycycline per kg weight, administered at every 12 hours, during 7 consecutive days or at the veterinarian’s discretion. The tablets can be administered together with food or dissolved in liquid. We recommend the continuation of a treatment for up to 48 hours after the clinical condition disappearance. Precautions Comply with dosages indicated for using the product. Only the veterinarian is able to do changes in the recommended dosage for using the product. If there is kidney dysfunction, the dose must be reduced in order to prevent excessive systemic accumulation. Contraindications and use limitations Do not administer to pregnant females. Do not administer to animals that are less than 30 days old. Do not administer the product with expired validity term. Drug interactions Do not administer to animals that are receiving treatment with barbiturates or phenytoin. Doxycycline absorption can be affected in presence of aluminum hydroxide, sodium bicarbonate, calcium and magnesium salts, and iron preparations. Do not administer together to antacids. The interaction with calcium salts can inhibit bone growth and tooth development. Adverse effects A prolonged treatment can cause gastrointestinal disorders, such as nausea, vomiting, and diarrhea, which can be minimized by the administration of the product jointly with food. The presence of food in the stomach does not compromise doxycycline absorption. Due to ability that doxycycline has of binding itself to calcium, it can cause heart arrhythmias.
Keep in dry and fresh place, protected from sunlight (between 15oC and 30oC), out of reach of children and domestic animals. Sale under prescription and administration under veterinary orientation. Licensed at the Ministry of Agriculture under no. 8862, on 05/07/04. Technical Responsible: Dr. Fausto Eduardo Fonseca Terra. CRMV/SP 10300 Validity term: 02 (two) years after the manufacturing date. Presentation Cartridge containing one blister with 14 tablets; cartridge containing 3 blisters with 14 tablets; and display containing 5 blisters with 14 tablets. OURO FINO pet Animal welfare 100% Brazilian, exporter, generating jobs in Brazil. Owner: Ouro Fino Saúde Animal Ltda. Rod. Anhangüera SP 330 KM 298 CEP: 14140-000 - Cravinhos - SP CNPJ: 57.624.462/0001-05 Phone/Fax: (16) 3518-2000 www.ourofino.com Made in Brazil Manufacturer: Almapal S.A Av, Eng. Heitor Antônio Eiras Garcia, 2756 Jardim Maria Luiza, São Paulo-SP CEP: 05564-000 CNPJ: 48.344.725/0001-23 50120189/0507 OF21
FREQUENTLY ASKED QUESTIONS REGARDING MUSHROOM NETWORKS' BBNA DEVICES What does BBNA stand for? Broadband Bonding Network Appliance What kind of BBNA devices are available? Currently, there are 5 models available, the Truffle 5201G, Truffle 6401, Porcini 4421, PortaBella 2242, PortaBella 141 and PortaBella 141i which differ in the number and type of WAN ports available and number o
scientific correspondence Diminished A␥T fetal globin levels in Sardinian haplo-type II ␤0-thalassaemia patients are associated with afour base pair deletion in the A␥T promoter. Br JHaematol 1991; 78:105-7. 9. Pistidda P, Frogheri L, Oggiano L, et al. Fetal hemo-globin expression in compound heterozygotes for -117(G→A) A␥ HPFH and ␤0 nonsense thalassemia. Am J10. Pistidda P, F